Id Counterfeit Pharmaceuticals with Portable Raman
Rigaku
Pfizer Takes Issue with European Commission’s Plans to Regulate ATMPs
 |
23-May-2013 - Pfizer and other EU industry and academic groups are calling on the European Commission to revise its plans for authorizing and regulating ATMPs (advanced therapy medical products). Related news |
News in brief
Pfizer Puts Lipitor Site Up For Sale as Patent Expiration Causes Over-Capacity
16-May-2013 - Lower sales of off-patent former blockbuster Lipitor have prompted Pfizer to try and sell off its third Irish API plant in as many years.
Coalition Calls for Science-Based Approach to Elemental Impurity Testing
15-May-2013 - Differences in elemental impurity standards being developed separately by the US Pharmacopeia and ICH could mean costly reformulations according to a pharmaceutical, API and excipient industry coalition.
Aesica Accesses Atom-Efficient Amide Tech in Academic Accord
14-May-2013 - Making amide bonds may be greener and cheaper in the future according to Aesica, which has partnered with UK scientists to commercialize a new synthesis technique.
Canada Solidifies GMP Requirements for APIs to Secure Supply Chain
14-May-2013 - Looking to align with other industrialized nations, Canada has agreed to extend its GMP requirements for all active pharmaceutical ingredients (APIs), according to a notice in the Canada Gazette .
Large Scale Manufacturing Drives AMRI Q1 Revenue Uptick
14-May-2013 - Large scale manufacturing revenue in the first quarter of 2013 increased 14% over the same quarter in 2012 as AMRI (Albany Medical Research Inc.) saw an 11% increase in overall revenue.
EMA Seeks to Revise Some Phthalate Limits in Excipients
08-May-2013 - The EMA may recommend new daily exposure limits for some phthalates as animal data have shown they can cause negative reproductive and development effects, according to a new draft guideline .
FDA Releases Alexion Response to Form 483 on Microbial Contaminations
07-May-2013 - In a rare move, the FDA has publically released Alexion Pharmaceuticals’ response to a Form 483 following inspection of its US site and the discovery of microbial contamination.
Ingredients: Featured news
Audio
Updated IPEC Guide Steers Excipient Manufacturers Away From Unnecessary Tests
John Giannone - incoming IPEC-Americas chairman
Irwin Silverstein, COO and VP of the International Pharmaceutical Excipients...
Gallery
Johnson Matthey to optimise API biz; Fine Chem forecasts roundup
in-Pharmatechnologist.com presents a roundup of news in the fine chemicals sector, beginning with Johnson Matthey which has started a review of its active pharmaceutical ingredient (API) business after competition in the UK impacted its third quarter margins.
